close
Home
#WE-WONT-REST
chevron_right
News & Events
chevron_right
About medicines
chevron_right
More Than Medicine
chevron_right
Pharmaceutical Legislation
Relationships & code
chevron_right
Publications
chevron_right
About us
chevron_right
Contact us
KMS Login
arrow_back
close
#WE-WONT-REST
Patient stories
expand_more
expand_less
chevron_right
Alzheimer's patient story
Blood cancer patient story
Lung cancer patient story
Haemophilia patient story
Members updates
Imagine
News & Events
The EFPIA View
Events
Newsletter
About medicines
Development of medicines
expand_more
expand_less
chevron_right
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Unmet medical need
Use of medicines
expand_more
expand_less
chevron_right
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
expand_more
expand_less
chevron_right
Back Innovation, Boost Access
More Than Medicine
Improving Health
Turning science into new medicines
Responsible Innovation
Economic impact
Pharmaceutical Legislation
Relationships & code
The EFPIA Code
Patient organisations
Healthcare professionals (HCPs)
Disclosure of payments
National codes
EU institutions
Publications
Data center
Downloads
Cancer Comparator Report
expand_more
expand_less
chevron_right
About
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
Cancer Types
Resources
About us
Who we are
EFPIA Japan
Membership
Job vacancies
Contact us
arrow_back
close
Development of medicines
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Unmet medical need
Use of medicines
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
Back Innovation, Boost Access
Cancer Comparator Report
About
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
Cancer Types
Resources
News & Events
The EFPIA view
Podcast: How can...
Podcast: How can we future-proof medicines regulation in the post-COVID world?
close
Podcast: How can we future-proof medicines regulation in the post-COVID world?
Welcome to 19 conversations
apps
The EFPIA View
chevron_left
Previous
print
Print
Next
chevron_right
Podcast: How can we future-proof medicines regulation in the post-COVID world?
09.03.21
Today we're asking Nathalie Moll, Director General of EFPIA, "How can we future-proof medicines regulation in the post-COVID world?".
close
continue